首页 | 本学科首页   官方微博 | 高级检索  
检索        

Exon—by—exon Screening for RB Germline Mutations Using Heteroduplex—SSCP Analysis
引用本文:QingJiong Zhang Kensei Minoda 等.Exon—by—exon Screening for RB Germline Mutations Using Heteroduplex—SSCP Analysis[J].眼科学报,1997,13(1):5-11.
作者姓名:QingJiong  Zhang  Kensei  Minoda
作者单位:Qingjiong Zhang,Kensei Minoda,Ruiping Zeng,Zhongyao Wu Xueshan Xiao,Shiqiang Li,Fengshen Zhang Zhongshan Ophthalmic Center; Department of Medica Genetics Sun Yat-sen University of Medical Sciences,Guangzhou 510060,China Department of Ophthalmology,Teikyo University Ichihara Hospital,Ichihara,Chiba 299 - 01,Japan.
基金项目:Guang Dong Provincial Natural Science Foundation (QZ:930354, 960149 ),the Misnistry of Public Health(QZ),the Ministry of Health and Welfare of Japan(KM),the Mishima Fund for Eye Research and International Exchange(QZ),the Sasagawa Medical Re
摘    要:Objective: To disclose the nature of RBI germline mutations in Chinese and to develop a practical and effective way for mutational screening. Methods: Leukocyte DNA was prepared from 8 Chinese patients with hereditary retinoblastoma. PCR combined with nonisotopic heteroduplex-SSCP analysis was used to screen leukocyte DNA for RBI germline mutations, exon-by-exon, without the use of restriction endonuclease digestion. The mutations were finally identified by sequencing. In order to testify the effectiveness of this method, the same method was used to detect other 17 samples which have been previously analyzed by other methods. Results: Heterozygous germline mutations were detected in the leukocyte DNA of 6 out of 8 Chinese patients;G del/codon 46,T del/codon 131 ,CAGAA del/condon 257 -258, GCAgta→GCAgca/donor of exon 16, C@T/codon 661, and C→T/codon 787. Heteroduplex-SSCP analysis may detect RBI germline mutations in 68% (177 25) unselected patients, which is more effective than SSCP(56%) or heterodupl

关 键 词:成视网膜细胞瘤  突变  SSCP  遗传因素  非遗传因素

Exon-by-exon Screening for RB Germline Mutations Using Heteroduplex-SSCP Analysis
Qingjiong Zhang,Kensei Minoda,Ruiping Zeng,Zhongyao Wu Xueshan Xiao,Shiqiang Li,Fengshen Zhang Zhongshan Ophthalmic Center.Exon-by-exon Screening for RB Germline Mutations Using Heteroduplex-SSCP Analysis[J].Eye Science,1997,13(1):5-11.
Authors:Qingjiong Zhang  Kensei Minoda  Ruiping Zeng  Zhongyao Wu Xueshan Xiao  Shiqiang Li  Fengshen Zhang Zhongshan Ophthalmic Center
Institution:Zhongshan Ophthalmic Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
Abstract:OBJECTIVE: To disclose the nature of RB1 germline mutations in Chinese and to develop a practical and effective way for mutational screening. METHODS: Leukocyte DNA was prepared from 8 Chinese patients with hereditary retinoblastoma. PCR combined with nonisotopic heteroduplex-SSCP analysis was used to screen leukocyte DNA for RB1 germline mutations, exon-by-exon, without the use of restriction endonuclease digestion. The mutations were finally identified by sequencing. In order to testify the effectiveness of this method, the same method was used to detect other 17 samples which have been previously analyzed by other methods. RESULTS: Heterozygous germline mutations were detected in the leukocyte DNA of 6 out of 8 Chinese patients: G del/codon 46, T del/codon 131, CAGAA del/codon 257-258, GCAgta-->GCAgca/donor of exon 16, C-->T/codon 661, and C-->T/codon 787. Heteroduplex-SSCP analysis may detect RB1 germline mutations in 68% (17/25) unselected patients, which is more effective than SSCP(56%) or heteroduplex analysis(64%) alone. The corrected RB1 mutation detection rate may be 80% if the samples were previously analyzed by Southern blotting, which is much higher than those reported on literature. CONCLUSION: Mutations involving a few base pairs in RB1 gene are common in Chinese. Heteroduplex-SSCP analysis is more useful and effective than SSCP or heteroduplex analysis alone for the rapid screening for unknown mutations.
Keywords:retinoblastoma  RB1  mutation  heteroduplex-SSCP  SSCP  heteroduplex
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号